Medicare changes effective August 7, 2025

CMS Coverage API · 16

• LCD L39469: MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis — Noridian

  LCD-L39469NoridianRheumatologysource ↗

• LCD L36113: MolDX: MGMT Promoter Methylation Analysis — CGS

  LCD-L36113CGS AdministratorsOncologysource ↗

• LCD L38694: Computed Tomography Cerebral Perfusion Analysis (CTP) — CGS

  LCD-L38694CGS AdministratorsRadiologysource ↗

• LCD L34562: Home Health Skilled Nursing Care-Teaching and Training: Alzheimer's Disease and Behavioral Disturbances — Palmetto GBA

  LCD-L34562Palmetto GBAHome Healthsource ↗

• LCD L39427: MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis — CGS

  LCD-L39427CGS AdministratorsRheumatologysource ↗

• LCD L34046: Speech-Language Pathology — CGS

  LCD-L34046CGS AdministratorsSpeech Therapysource ↗

• LCD L33996: Vitamin D Assay Testing — CGS

  LCD-L33996CGS AdministratorsClinical Laboratorysource ↗

• LCD L33942: Physical Therapy - Home Health — CGS

  LCD-L33942CGS AdministratorsHome Healthsource ↗

• LCD L34063: RAST Type Tests — CGS

  LCD-L34063CGS AdministratorsAllergy/Immunologysource ↗

• LCD L36192: MolDX: MGMT Promoter Methylation Analysis — Noridian

  LCD-L36192NoridianOncologysource ↗

• LCD L34538: Hospice Determining Terminal Status — CGS

  LCD-L34538CGS AdministratorsHospicesource ↗

• LCD L38920: Off-label Use of Rituximab and Rituximab Biosimilars — CGS

  LCD-L38920CGS AdministratorsOncologysource ↗

• LCD L34061: Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI) — CGS

  LCD-L34061CGS AdministratorsOphthalmologysource ↗

• LCD L34200: Removal of Benign Skin Lesions — CGS

  LCD-L34200CGS AdministratorsDermatologysource ↗

• LCD L36485: MolDX: HLA-DQB1*06:02 Testing for Narcolepsy — CGS

  LCD-L36485CGS AdministratorsNeurologysource ↗

• LCD L34246: Routine Foot Care and Debridement of Nails — CGS

  LCD-L34246CGS AdministratorsOrthopedicssource ↗